<?xml version="1.0" encoding="UTF-8"?>
<p id="para150">The epidemic infectious diseases included in this study were selected from WHO's original blueprint list of priority emerging infectious diseases.
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> This list has recently been updated to exclude chikungunya and severe fever with thrombocytopenia syndrome,
 <xref rid="bib5" ref-type="bibr">
  <sup>5</sup>
 </xref> but we include these in our analysis as they are still assumed to have considerable epidemic disruption potential. We drew our probability of success data from the preclinical phase literature (
 <xref rid="tbl1" ref-type="table">table 1</xref> ).
 <xref rid="bib3" ref-type="bibr">3</xref>, 
 <xref rid="bib6" ref-type="bibr">6</xref>, 
 <xref rid="bib12" ref-type="bibr">12</xref>, 
 <xref rid="bib13" ref-type="bibr">13</xref>, 
 <xref rid="bib14" ref-type="bibr">14</xref>, 
 <xref rid="bib15" ref-type="bibr">15</xref>, 
 <xref rid="bib16" ref-type="bibr">16</xref> The remainder of our data collection efforts focused on vaccine candidate identification and on associated costs. Whereas vaccine candidates were identified through a two-step approach involving a literature review and a survey, cost data were collected via self-reporting in a survey and via mining CEPI's own database of projects and associated budgets.
</p>
